Immunizations

GSK's Menveo one-vial presentation, which is used to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W, will initially be available to U.S. federal customers, with broader availability anticipated in mid-2023.

The booster shot is authorized for people 18 and older who, for medical or accessibility reasons, cannot take one of the bivalent messenger RNA COVID-19 boosters.